1 / 6

Soft Tissue Sarcoma Therapeutic Development Pipeline Review H1 2015

This report gives far reaching data on the restorative advancement for Soft Tissue Sarcoma, complete with similar examination at different stages, therapeutics evaluation by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent redesigns, and included news and press discharges. It additionally audits key players included in the restorative improvement for Soft Tissue Sarcoma and uncommon elements on late-stage and ceased activities.

john2222deere
Télécharger la présentation

Soft Tissue Sarcoma Therapeutic Development Pipeline Review H1 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Soft Tissue Sarcoma - Pipeline Review, H1 2015 By RnRMarketResearch.com Publisher Name : Global Market Direct Date: 29-May-2015 No. of pages: 386 Single User License: US $2000 Browse more Reports on Cancer Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Soft Tissue Sarcoma - Pipeline Review, H1 2015 RnRMarketResearch.com Adds “Soft Tissue Sarcoma - Pipeline Review, H1 2015” which provides an overview of the Soft Tissue Sarcoma therapeutic pipeline. This report gives far reaching data on the restorative advancement for Soft Tissue Sarcoma, complete with similar examination at different stages, therapeutics evaluation by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent redesigns, and included news and press discharges. It additionally audits key players included in the restorative improvement for Soft Tissue Sarcoma and uncommon elements on late-stage and ceased activities. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Soft Tissue Sarcoma - Pipeline Review, H1 2015 Companies Discussed/Mentioned in this Research : Advenchen Laboratories, LLC, Altor BioScience Corporation, Amgen Inc., Bayer AG, Bellicum Pharmaceuticals, Inc., BoehringerIngelheim GmbH, CASI Pharmaceuticals Inc., Celgene Corporation, Cellectar Biosciences, Inc., CytRx Corporation, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, EpiZyme, Inc., Exelixis, Inc., Gem Pharmaceuticals, LLC, Immune Design Corp., Karyopharm Therapeutics, Inc., Loxo Oncology, Inc., MedImmune, LLC, Merck & Co., Inc., Merrimack Pharmaceuticals, Inc., and more.. Drugs Profile Discussed in this Research : afatinib, AL-3818, aldoxorubicin hydrochloride, ALT-836, APC-103, belinostat, BI-853520, C-21, cabazitaxel, cabozantinib s-malate, cancer vaccine, Cell Therapy 2 for Oncology and Infectious Disease, Cell Therapy for GD2 Expressing Solid Tumors, Cell Therapy to Target LMP-1 and LMP-2 for Oncology, Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases, and more.. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Soft Tissue Sarcoma - Pipeline Review, H1 2015 Scope For Soft Tissue Sarcoma - Pipeline Review, H1 2015 • The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Soft Tissue Sarcoma - Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Soft Tissue Sarcoma - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related